DES

Across TCGA pan-cancer cohorts, DES mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DES data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher DES mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated DES expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where DES mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.917	0.777	.002	21	view →
LUAD	DFS	Tertile	II,III,IV	0.787	0.991	.016	9	view →
LSCC	DFS	Median	All	0.991	0.560	.016	7	view →
GBM	OS	Quartile	All	0.393	0.644	.037	3	view →
HNSC	DFS	Tertile	III,IV	1.000	0.911	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DES–PDAC (OS)

Open the PDAC breakdown →